SNMMI president weighs in on Lymphoseek approval

03/17/2013 | DOTMed.com

SNMMI President Frederic H. Fahey said Lymphoseek, recently approved by the FDA to map the spread of cancer, will improve diagnoses. The drug "lets you be more confident that you are taking the correct lymph node out," Fahey said. The agent employs a targeted approach to seek out the sentinel lymph node, and it can stay in place longer, which can be more convenient for patients, Fahey said.

View Full Article in:

DOTMed.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA